Lactobacillus plantarum CCFM8661 alleviates lead toxicity in mice.
Lead causes a broad range of adverse effects in humans and animals. The objective was to evaluate the potency of lactobacilli to bind lead in vitro and the protective effects of a selected Lactobacillus plantarum CCFM8661 against lead-induced toxicity in mice. Nine strains of bacteria were used to investigate their binding abilities of lead in vitro, and L. plantarum CCFM8661 was selected for animal experiments because of its excellent lead binding capacity. Both living and dead L. plantarum CCFM8661 were used to treat 90 male Kunming mice during or after the exposure to 1 g/L lead acetate in drinking water. The results showed oral administration of both living and dead L. plantarum CCFM8661 offered a significant protective effect against lead toxicity by recovering blood δ-aminolevulinic acid dehydratase activity, decreasing the lead levels in blood and tissues, and preventing alterations in the levels of glutathione, glutathione peroxidase, malondialdehyde, superoxide dismutase, and reactive oxygen species caused by lead exposure. Moreover, L. plantarum CCFM8661 was more effective when administered consistently during the entire lead exposure, not after the exposure. Our results suggest that L. plantarum CCFM8661 has the potency to provide a dietary strategy against lead toxicity.
State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, People's Republic of China.
Fengwei
F
Tian
Qixiao
Q
Zhai
Jianxin
J
Zhao
Xiaoming
X
Liu
Gang
G
Wang
Hao
H
Zhang
Heping
H
Zhang
Wei
W
Chen
D000818:Animals; D015415:Biomarkers / Q000032:analysis / Q000097:blood / Q000378:metabolism; D002614:Chelating Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D015913:Chelation Therapy / Q000009:adverse effects; D006358:Hot Temperature; D048191:Lactiplantibacillus plantarum / Q000254:growth & development / Q000378:metabolism; D007854:Lead / Q000032:analysis / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics; D007855:Lead Poisoning / Q000178:diet therapy / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D050296:Microbial Viability; D009942:Organometallic Compounds / Q000008:administration & dosage; D018384:Oxidative Stress; D000623:Porphobilinogen Synthase / Q000037:antagonists & inhibitors / Q000097:blood / Q000737:chemistry; D019936:Probiotics / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D011897:Random Allocation; D017382:Reactive Oxygen Species / Q000097:blood; D004113:Succimer / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D014018:Tissue Distribution / Q000187:drug effects
D015415:Biomarkers; D002614:Chelating Agents; D009942:Organometallic Compounds; D017382:Reactive Oxygen Species; D007854:Lead; D004113:Succimer; D000623:Porphobilinogen Synthase; C008261:lead acetate